-
Kinetic Concepts Said to Be in Talks With Two Private-Equity Firms; Valued at ~$5B
Wednesday, July 6, 2011 - 10:57am | 156According to this Bloomberg article, Kinetic Concepts is in discussions with a least two private-equity firms to go private in a leveraged buyout. The market value of the company after yesterday's close was $4.3 billion, in which the private-equity firms value Kinetic at $5 billion. Shares spiked...
-
Piper Jaffray Updates 7/6
Wednesday, July 6, 2011 - 9:14am | 483Piper Jaffray made a number of updates in a research report published today. Changyou.com (NASDAQ: CYOU) had its rating maintained at Overweight. At the same time, its price target was raised from $49 to $53. On Tuesday, CYOU closed the day at $45.32. Conway (NYSE: CNW) had its rating reiterated...
-
Rodman & Renshaw Maintains Market Underperform on NxStage Medical
Wednesday, July 6, 2011 - 9:01am | 63Rodman & Renshaw is out with its report today on NxStage Medical (NASDAQ: NXTM), maintaining Market Underperform. In a note to clients, Rodman & Renshaw writes, "We maintain our Market Underperform rating and PT of $18, which is 5x forward sales on the core home-hemo business and 1.2x on...
-
ResMed Announces Acquisition of BiancaMed
Wednesday, July 6, 2011 - 8:04am | 71ResMed Inc. (NYSE: RMD) announced today that it has acquired BiancaMed Ltd., a leading Irish medical technology company. ResMed purchased all of BiancaMed's outstanding shares with cash. BiancaMed will become a part of ResMed's newly-created Ventures and Initiatives unit. ResMed estimates the...
-
JP Morgan Initiates Coverage of Quidel with Neutral and PT of $16
Wednesday, July 6, 2011 - 7:45am | 51JP Morgan initiated its coverage of Quidel (NASDAQ: QDEL) with a Neutral rating and a price target of $16. On Tuesday, Quidel added 3.92% to its value to stand around $15.90. Its shares lost most of yesterday's gains in today's pre-market trading, however, after falling 3.77% to $15.30.
-
UPDATE: Piper Jaffray Color on MAKO Surgical PT Increase
Wednesday, July 6, 2011 - 7:43am | 124Piper Jaffray, which raised its PT on shares of MAKO Surgical (NASDAQ: MAKO), is providing some color on the stock. “Our survey of current MAKO customers indicates that the surgical preference evaluation group is expanding to a wider group of sites and surgeons, and interest among other customers...
-
JP Morgan Initiates Quidel At Neutral, $16 PT
Wednesday, July 6, 2011 - 6:48am | 24JP Morgan has initiated coverage on Quidel (NASDAQ: QDEL) with a Neutral rating and $16 price target.
-
Piper Jaffray Raises PT On MAKO Surgical To $35
Wednesday, July 6, 2011 - 6:42am | 28Piper Jaffray has raised the price target on MAKO Surgical Corporation (NASDAQ: MAKO) from $33 to $35 and maintains its Overweight rating.
-
Market After Last Week's Rally 07-05-2011
Tuesday, July 5, 2011 - 2:57pm | 927Cusick's Corner Because of an absence of trading catalysts, the market is likely to stay in a range for the rest of the day and just continue to chop around. This makes the current market a little more difficult to trade, at least from a two-sided perspective. I previously noted that spreading...
-
Biggest Winners and Losers After the Opening Bell
Tuesday, July 5, 2011 - 10:09am | 180Winners: Yamana Gold (NYSE: AUY) is up over 4.50%, trading near $12 after gold rallied nearly 1%. Silver Wheaton (NYSE: SLW) is up over 4.30%, trading near $33.80 after silver rallied near 2.50%. Charter Communications (NASDAQ: CHTR) is up over 3.25%, trading near $56.95. Netflix (NASDAQ: NFLX...
-
Rodman & Renshaw Reiterates Market Outperform and PT of $9 on Spectranetics
Tuesday, July 5, 2011 - 9:30am | 43Rodman & Renshaw reiterated its Market Outperform rating on Spectranetics (NASDAQ: SPNC). At the same time, the rating agency left its price target on the company's stock unchanged at $9. On Friday, Spectranetics finished the week at $6.28.
-
JP Morgan Provides Color on Medtronic
Tuesday, July 5, 2011 - 9:09am | 173JP Morgan provided color on Medtronic (NYSE: MDT). In a research report published today, the rating agency commented on the criticism on the company's Infuse product. In the report, JP Morgan states, “Last Tuesday (6/28) The Spine Journal released a scathing criticism of Medtronic's Infuse....
-
JP Morgan Reiterates Overweight and PT of $26 on NxStage Medical
Tuesday, July 5, 2011 - 9:05am | 43JP Morgan reiterated its Overweight rating on NxStage Medical (NASDAQ: NXTM). At the same time, the rating agency left its price target on the company's stock unchanged at $26. On Friday, NXTM closed the day at $20.98.
-
Citi Maintains Sell Rating on Hospira
Tuesday, July 5, 2011 - 8:58am | 70Citi is maintaining its Sell rating on shares of Hospira (NYSE: HSP). “We maintain our Sell rating, as we remain cautious on increasing competitive pressures along with downside risk to 2012 consensus EPS,” Citi writes. “We leave our 2011 $4.04 EPS estimate unchanged though we lower 2H (offset by...
-
IVAX Diagnostics Announces Initial Closing of Investment and Prepares for Expansion and Acquisitions
Tuesday, July 5, 2011 - 8:46am | 286IVAX Diagnostics (NYSE: IVD) announced today that it has consummated the initial transactions contemplated by its previously announced stock purchase agreement with ERBA Diagnostics Mannheim GmbH. At the initial closing of the investment, IVAX Diagnostics received an aggregate purchase price of $...